CureDuchenne Ventures is pleased to share that one of our research investments, Code Bio, has announced that have secured $75 million in additional investments to advance their gene therapy programs […]
We’re thrilled to share news about Code Biotherapeutics, a company pioneering targeted non-viral delivery of genetic medicines. CureDuchenne’s April 2021 research investment into Code Biotherapeutics was based on extensive preclinical […]
Today, CureDuchenne Ventures is pleased to share that we made a research investment into Code BioTherapeutics and their next-generation gene therapy platform. This is a promising technology aimed at overcoming […]
